Dechra Introduces New Mirataz Pack Size And Packaging
10 hours ago 
55 views
Dechra has introduced a new pack size and packaging for Mirataz, the company’s transdermal treatment for feline weight gain.
The new, smaller Mirataz 3g pack will help improve sustainability by providing a more appropriate quantity of the treatment within the open shelf life of 30 days, while the packaging consists of a childproof cap tube and a simple cardboard pack to reduce packaging waste and plastic usage. The 3g pack replaces the 5g pack previously available and addresses feedback from veterinary professionals demonstrating that Dechra values their insights.
Mirataz is the first and only licensed transdermal mirtazapine ointment for cats in Europe and is licensed for managed body weight gain in cats suffering from poor appetite and weight loss as a result of chronic medical conditions. The ointment can induce significant weight gain in as little as 14 days (Poole et al., 2019), which allows for a swift response to the initial signs of weight loss and lack of appetite and can improve the condition and wellbeing of the patient before a definitive diagnosis has been made.
Administered topically daily by applying a 3.8cm ribbon of ointment (approximately 2mg per cat, equal to 0.1ml), Mirataz should be applied with a gloved hand onto the inner pinna of the cat’s ear.
“Early intervention in feline weight management not only improves long-term health outcomes and prevents complications but also enhances owner satisfaction and loyalty,” comments Callum Watkins, brand manager at Dechra. “The new Mirataz 3g pack size delivers precise dosing for better client compliance while significantly reducing product and packaging waste. This innovation not only supports sustainability but also aligns with a vet practice’s commitment to providing high-quality, responsible care to patients.”
For further information on Mirataz contact your local Dechra account manager or go online.
More from Dechra